Previous 10 | Next 10 |
Verastem (NASDAQ: VSTM ): Q1 GAAP EPS of -$0.52 misses by $0.05 . Revenue of $1.67M misses by $1.15M . Press Release More news on: Verastem, Inc., Earnings news and commentary, Healthcare stocks news, ,
Company Reports $1.7 Million in Net Product Revenues from COPIKTRA™; Issues Product Revenue Guidance for 2019 Cash, Cash Equivalents and Short-Term Investments of $211.7 Million as of March 31, 2019 Company to Host Conference Call Today at 4:30 PM ET Verastem, Inc. (N...
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will host a conference call and webcast on...
Verastem Oncology ( VSTM ) was hot stock over the course 2018 in anticipation of its now approved drug, Copiktra. Following approval, VSTM plummeted as investors realized there wasn't going to be a big partnership or buyout. The share price fallout continued after a lackluster Q4 earnings repo...
New Terms Provide for Lower Interest Rate and Longer Interest-Only Payment Period Verastem, Inc. (Nasdaq: VSTM) operating as Verastem Oncology, (or the “Company”), focused on developing and commercializing medicines seeking to improve the survival and quality of life of ...
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday...
Editor's note: Seeking Alpha is proud to welcome David DeWitt as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » It has been ...
Verastem ( VSTM ) is now a commercial stage biotechnology pharmaceutical company with one approved drug, Copiktra. Verastem's stock price has fallen since it received its FDA approval. This reflects stock market conditions in Q4 2018, overenthusiasm leading up to the approval, and Verastem bei...
VivoPower International (NASDAQ: VVPR ) -21% . More news on: VivoPower International PLC, Navios Maritime Holdings Inc., Express, Inc., Stocks on the move, Read more ...
Verastem, Inc (VSTM) Q4 2019 Results Earnings Conference Call March 12, 2019 04:30 PM ET Company Participants Robert Forrester - CEO Rob Gagnon - Chief Financial Officer Joseph Lobacki - Chief Commercial Officer Dan Paterson - Chief Operating Officer Conference Call Partic...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...